These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

368 related items for PubMed ID: 7032534

  • 1. Clinical research into the hypolipemic and platelet antiaggregant activity of plafibride, Carried out in double-blind conditions and in comparison with clofibrate.
    Palmieri B, Gasparini Casari M, DiBlasio P, Zirilli E.
    Arzneimittelforschung; 1981; 31(10a):1863-6. PubMed ID: 7032534
    [Abstract] [Full Text] [Related]

  • 2. Plafibride: clinical trial of a new platelet antiaggregating agent.
    Olivella J, Vicens B.
    Arzneimittelforschung; 1981; 31(10a):1856-8. PubMed ID: 7032532
    [Abstract] [Full Text] [Related]

  • 3. Clinical trials of plafibride in geriatric patients.
    Demichelis Genesio MA, Bracons R, Vicens B, Zapatero J, Bruseghini L.
    Arzneimittelforschung; 1981; 31(10a):1852-5. PubMed ID: 7198465
    [Abstract] [Full Text] [Related]

  • 4. Plafibride tolerance trial in healthy volunteers.
    Dalmau J, Vicens B, Zapatero J, Bruseghini L.
    Arzneimittelforschung; 1981; 31(10a):1845-9. PubMed ID: 7198463
    [Abstract] [Full Text] [Related]

  • 5. Double-blind study on the activity of plafibride in the treatment of type IV hyperlipoproteinemia.
    Ferreira IJ, del Rio A, González-Viejo N, Vicens B.
    Arzneimittelforschung; 1981; 31(10a):1859-62. PubMed ID: 7032533
    [Abstract] [Full Text] [Related]

  • 6. Platelet antiaggregant activity of plafibride ex vivo in rat, dog and rabbit.
    Bruseghini L, Vilageliu J, Freixes J.
    Arzneimittelforschung; 1981; 31(10a):1790-5. PubMed ID: 6797443
    [Abstract] [Full Text] [Related]

  • 7. Hypolipemic activity of plafibride.
    Bruseghini L, Vilageliu J, Bagaria A.
    Arzneimittelforschung; 1981; 31(10a):1796-800. PubMed ID: 7198456
    [Abstract] [Full Text] [Related]

  • 8. Plafibride tolerance trial at increasing doses in healthy volunteers.
    Dalmau J, Vicens B, Zapatero J, Bruseghini L.
    Arzneimittelforschung; 1981; 31(10a):1840-4. PubMed ID: 7198462
    [Abstract] [Full Text] [Related]

  • 9. Synthesis and pharmacological evaluation of N'-morpholinomethylurea derivatives with platelet antiaggregant activity.
    Ribalta JM, Artús JJ, Salvador L, Roma E, Vilageliu J, Freixes J, Bruseghini L.
    Arzneimittelforschung; 1981; 31(10a):1782-6. PubMed ID: 6797442
    [Abstract] [Full Text] [Related]

  • 10. Bioavailability of plafibride in healthy volunteers.
    Santaniello E, Conti F, Vilageliu J, Bruseghini L.
    Arzneimittelforschung; 1981; 31(10a):1850-2. PubMed ID: 7198464
    [Abstract] [Full Text] [Related]

  • 11. Hypolipemic profile of plafibride in a model of experimental atherosclerosis.
    Badimón JJ, Padró T, Cánovas M, Vidal M, Villaverde CA.
    Methods Find Exp Clin Pharmacol; 1983 Nov; 5(9):613-7. PubMed ID: 6668971
    [Abstract] [Full Text] [Related]

  • 12. Influence of plafibride, an antiplatelet and hypolipemic agent, on prostacyclin and thromboxane synthesis, 3',5'-cyclic AMP phosphodiesterase activity and serum clearance of a lipid emulsion.
    Vilageliu J, Freixes J, Giráldez A, Bermejo P, Basi N, Bruseghini L.
    Arzneimittelforschung; 1981 Nov; 31(10a):1805-7. PubMed ID: 6274363
    [Abstract] [Full Text] [Related]

  • 13. [Plafibride treatment of hyperlipidemias type II and IV].
    Soler J, Vinzia C, Gómez JM, Morató J.
    Med Clin (Barc); 1984 May 19; 82(19):840-2. PubMed ID: 6738212
    [No Abstract] [Full Text] [Related]

  • 14. [Double-blind study of the therapeutic activity of a new hypolipemic drug: etofibrate].
    Altomonte L, Mingrone G, Negrini A, De Cunto F, Greco AV.
    Clin Ter; 1981 Jan 15; 96(1):31-8. PubMed ID: 7016409
    [No Abstract] [Full Text] [Related]

  • 15. [An alternative in the therapy of primary hyperlipemias: etofibrate in depot preparations].
    Füsgen I, Summa JD.
    Med Klin; 1980 Nov 07; 75(23):823-5. PubMed ID: 7442597
    [Abstract] [Full Text] [Related]

  • 16. Pharmacokinetic approach of plafibride in rat.
    Zapatero D, Vilageliu J, Torres A, Ribalta JM, Bruseghini L.
    Arzneimittelforschung; 1981 Nov 07; 31(10a):1800-4. PubMed ID: 7198457
    [Abstract] [Full Text] [Related]

  • 17. [Therapeutic effects of bezafibrate in hyperlipidemia].
    Kunesová M, Honková M, Zeman M, Mares P, Skorepa J.
    Cas Lek Cesk; 1983 May 20; 122(20):628-31. PubMed ID: 6342789
    [No Abstract] [Full Text] [Related]

  • 18. [Controlled clinical trial of a new drug (plafibride) for the treatment of hyperlipoproteinemia type IV (author's transl)].
    Ferreira Montero IJ, Gutiérrez Martín M, del Río Ligorit A, Casasnovas Lenguas JA, Cornudella Lacasa R.
    Med Clin (Barc); 1982 May 01; 78(9):380-5. PubMed ID: 7047926
    [No Abstract] [Full Text] [Related]

  • 19. Activity of plafibride on erythrocyte deformability.
    Vilageliu J, Freixes J, Bruseghini L.
    Arzneimittelforschung; 1983 May 01; 33(3):401-4. PubMed ID: 6683514
    [Abstract] [Full Text] [Related]

  • 20. Improvement of hyperlipidaemia by bezafibrate treatment in RDT patients.
    Grützmacher P, Scheuermann E, Lang W.
    Proc Eur Dial Transplant Assoc; 1981 May 01; 18():169-75. PubMed ID: 7036147
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 19.